AR047267A1 - Proceso para la preparacion de derivados de pirimidina. - Google Patents

Proceso para la preparacion de derivados de pirimidina.

Info

Publication number
AR047267A1
AR047267A1 ARP040104521A ARP040104521A AR047267A1 AR 047267 A1 AR047267 A1 AR 047267A1 AR P040104521 A ARP040104521 A AR P040104521A AR P040104521 A ARP040104521 A AR P040104521A AR 047267 A1 AR047267 A1 AR 047267A1
Authority
AR
Argentina
Prior art keywords
substituted
sulfonyl
hydrogen
alkyl
same
Prior art date
Application number
ARP040104521A
Other languages
English (en)
Inventor
Joshi Narendra
Bhaskar Bhirud Shekhar
Batchu Chandrasekhar
Eswara Rao
Subhash Damle
Original Assignee
Glenmark Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34655267&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR047267(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glenmark Pharmaceuticals Ltd filed Critical Glenmark Pharmaceuticals Ltd
Publication of AR047267A1 publication Critical patent/AR047267A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

Un proceso para la preparacion de derivados de pirimidina, que comprende hacer reaccionar un reactivo de Wittig de la formula general (1), en donde R es alquilo C1-10, arilo o arilalquilo; R1 es un grupo hidrocarbonado sustituido o insustituido; R2 y R3 son iguales o diferentes y son hidrogeno o un grupo hidrocarbonado sustituido o insustituido; Z es un azufre, oxígeno, sulfonilo o imino que puede estar sustituido con formilo, acetilo, propionilo, butirilo, isobutirilo, valerilo, isovalerilo, amino sustituido con sulfonilo o alquilsulfonilo, y sulfonilo sustituido con alquilo, amino o alquilamino y X es un halogeno; con un aldehído de la formula general (2), en donde R4 es hidrogeno, un alquilo inferior o un cation capaz de formar una sal no toxica aceptable para uso farmacéutico y cada R5 es igual o diferente y es hidrogeno o un grupo protector hidrolizable, o cada R5 está unido al mismo sustituyente que está unido con cada átomo de oxígeno para formar un grupo protector hidrolizable, en presencia de una base.
ARP040104521A 2003-12-04 2004-12-03 Proceso para la preparacion de derivados de pirimidina. AR047267A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1244MU2003 2003-12-04
US56173204P 2004-04-13 2004-04-13

Publications (1)

Publication Number Publication Date
AR047267A1 true AR047267A1 (es) 2006-01-11

Family

ID=34655267

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104521A AR047267A1 (es) 2003-12-04 2004-12-03 Proceso para la preparacion de derivados de pirimidina.

Country Status (4)

Country Link
US (1) US7312329B2 (es)
AR (1) AR047267A1 (es)
TW (1) TW200518757A (es)
WO (1) WO2005054207A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1417180T3 (da) * 2001-07-13 2007-04-10 Astrazeneca Uk Ltd Fremstilling af aminopyrimidinforbindelser
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0321827D0 (en) * 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
GB0324791D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
EP1797046A2 (en) * 2004-09-27 2007-06-20 Ranbaxy Laboratories Limited Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium
GB0428328D0 (en) * 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
JP5146965B2 (ja) * 2005-06-24 2013-02-20 レツク・フアーマシユーテイカルズ・デー・デー 不純物を含まない非晶質ロスバスタチンカルシウムの調製方法
SI1915349T1 (sl) 2005-06-24 2016-05-31 Lek Pharmaceuticals D.D. Postopek za pripravo čistega amorfnega rosuvastatin kalcija
GB0514078D0 (en) * 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
EP1912953B1 (en) * 2005-07-28 2016-08-17 LEK Pharmaceuticals d.d. Process for the synthesis of rosuvastatin calcium
US20070099994A1 (en) 2005-08-16 2007-05-03 Valerie Niddam-Hildesheim Rosuvastatin calcium with a low salt content
US7868169B2 (en) * 2005-08-16 2011-01-11 Teva Pharmaceutical Industries, Ltd. Crystalline rosuvastatin intermediate
WO2007125547A2 (en) 2006-05-03 2007-11-08 Manne Satyanarayana Reddy Novel process for statins and its pharmaceutically acceptable salts thereof
WO2007132482A2 (en) * 2006-05-17 2007-11-22 Manne Satyanarayana Reddy Novel process for the preparation of pitavastatin and its pharmaceutically acceptable salts
HUE028475T2 (en) * 2006-10-09 2016-12-28 Msn Laboratories Private Ltd A novel process for the preparation of statins and their pharmaceutically acceptable salts
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process
CN101376647B (zh) * 2007-08-31 2010-12-08 中山奕安泰医药科技有限公司 一种用于合成瑞舒伐他汀中间体及瑞舒伐他汀的合成方法
WO2009157014A2 (en) * 2008-01-30 2009-12-30 Cadila Healthcare Limited A process for preparing hmg-coa reductase inhibitors and intermediates
WO2010047296A1 (ja) 2008-10-20 2010-04-29 株式会社カネカ 新規ピリミジン誘導体およびＨＭＧ－ＣｏＡ還元酵素阻害剤中間体の製造方法
WO2010081861A1 (en) 2009-01-14 2010-07-22 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of rosuvastatin
US8487105B2 (en) 2009-01-19 2013-07-16 Msn Laboratories Limited Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof
EP2264015A1 (en) * 2009-02-02 2010-12-22 LEK Pharmaceuticals d.d. Key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof
US8987444B2 (en) 2010-01-18 2015-03-24 Msn Laboratories Private Limited Process for the preparation of amide intermediates and their use thereof
KR101134021B1 (ko) * 2010-02-24 2012-04-05 주식회사 메디켐코리아 새로운 중간체를 이용하는 피타바스타틴 헤미칼슘의 신규한 제조방법
EP2560970A1 (en) 2010-04-23 2013-02-27 Ranbaxy Laboratories Limited NOVEL INTERMEDIATES FOR THE PREPARATION OF HMG-CoA REDUCTASE INHIBITORS
CA2987775C (en) 2011-04-01 2019-01-08 Lonza Ltd Preparation of 3,5-dioxo hexanoate ester in two steps
WO2012153950A2 (ko) * 2011-05-06 2012-11-15 웰이앤씨 주식회사 ｔ-부틸 2-((4Ｒ,6Ｓ)-6-포밀-2,2-디메틸-1,3-디옥산-4-일)아세테이트의 제조방법
KR101368974B1 (ko) * 2011-07-27 2014-02-28 미래파인켐 주식회사 신규한 로수바스타틴 중간체, 이의 제조방법 및 이를 이용한 로수바스타틴 헤미칼슘염의 제조방법
KR20130087153A (ko) * 2012-01-27 2013-08-06 코오롱생명과학 주식회사 로수바스타틴의 제조방법 및 이에 사용되는 중간체 화합물
WO2013185309A1 (zh) * 2012-06-13 2013-12-19 上海迪赛诺药业有限公司 瑞舒伐他汀钙及其中间体的制备方法
US9850213B2 (en) * 2013-11-25 2017-12-26 Jiangxi Boya Seehot Pharmaceutical Co., Ltd. Method for preparing rosuvastatin sodium
CN103570762B (zh) * 2013-11-25 2015-12-09 复旦大学 ((4-对氟苯基-6-异丙基-2-(n-甲基甲磺酰胺基)-5-吡啶基)甲基)三苯基鏻盐的制备方法
WO2015131405A1 (zh) * 2014-03-07 2015-09-11 凯莱英医药集团（天津）股份有限公司 用于制备瑞舒伐他汀钙的中间体化合物以及由其制备瑞舒伐他汀钙的方法
CN104030989A (zh) * 2014-05-16 2014-09-10 南通常佑药业科技有限公司 一种瑞舒伐他汀钙的制备方法
CN104788388A (zh) * 2015-05-02 2015-07-22 江苏诚信药业有限公司 一种用于瑞舒伐他汀钙制备的工艺系统
CN104829600B (zh) * 2015-05-05 2017-11-07 浙江新东港药业股份有限公司 一种合成瑞舒伐他汀的中间体的合成工艺
CN105153039B (zh) * 2015-07-17 2018-01-12 江西富祥药业股份有限公司 一种瑞舒伐他汀钙中间体杂质的制备方法
CN107445992A (zh) * 2017-06-19 2017-12-08 浙江美诺华药物化学有限公司 一种罗舒伐他汀钙中间体的合成方法
CN109824724A (zh) * 2017-11-23 2019-05-31 上虞京新药业有限公司 一种瑞舒伐他汀钙中间体的制备方法
CN112521375A (zh) * 2019-09-17 2021-03-19 鲁南制药集团股份有限公司 一种瑞舒伐他汀钙中间体的制备方法
CN110940764B (zh) * 2019-12-31 2022-06-28 湖南九典制药股份有限公司 一种他汀类药物光学异构体的分离方法
CN114671859A (zh) * 2022-03-29 2022-06-28 苏州东瑞制药有限公司 一种瑞舒伐他汀钙及其中间体的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
KR100511533B1 (ko) * 2002-04-09 2005-08-31 임광민 키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법
WO2004103977A2 (en) * 2003-05-21 2004-12-02 Ciba Specialty Chemicals Holding Inc. Process for the preparation of pyrimidine derivatives

Also Published As

Publication number Publication date
US7312329B2 (en) 2007-12-25
TW200518757A (en) 2005-06-16
WO2005054207A1 (en) 2005-06-16
US20050124639A1 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
AR047267A1 (es) Proceso para la preparacion de derivados de pirimidina.
AR053109A1 (es) DERIVADOS DE PIPERIDINA Y PIPERAZINA, UN METODO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y SU USO EN LA ELABORACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR EL RECEPTOR DE QUIMIOQUINA CCR2.
ES2221440T3 (es) Derivados de acido aminofenoxiacetico como neuroprotectores.
PE20050896A1 (es) Intermediarios de quinolina como inhibidores de tirosina quinasas de receptores y la sintesis de los mismos
HUP0300329A2 (hu) Malonaminsavak és származékai és alkalmazásuk pajzsmirigy receptor ligandumként és ezeket tartalmazó gyógyszerkészítmények előállítására
MY114679A (en) Aroyl-piperidine derivatives
CO5690593A2 (es) Nuevos derivados de pirimidin 2-amina
PE20020104A1 (es) Derivados de benzotiazol
ECSP067053A (es) 1-aza-biciclo[3.3.1]nonanos
CA2161542A1 (en) Novel 5-Pyrrolyl-2-Pyridylmethylsulfinyl Benzimidazole Derivatives
BR9916566A (pt) Complexo de inibidor de ras-farnesiltransferase esulfobutiléter-7-ß-ciclodextrina ou2-hidroxipropil-ß-ciclodextrina e processo
CO5611126A2 (es) Derivados de indolinona utiles como inhibidores de la proteina cinasa
DE69530094D1 (de) Thiazolidindione derivate, ihre herstellung und verwendung
NO20071008L (no) Fremgangsmate for fremstilling av N-piperidino-1,5-difenylpyrazol-3-karboksamidderivater
BR9913405A (pt) Composto heterocìclico que contenha oxigênio, e, inibidor de fosfodiesterase (pde) iv.
DE602004020730D1 (de) Pharmazeutisches verfahren und damit hergestellte verbindungen
AR039111A1 (es) Tiopirimidinas e isotiazolpirimidinas inhibidoras de quinasas
HRP20080207T3 (en) Benzothiazole derivatives as adenosine receptor ligands
AR033300A1 (es) Compuestos de cefem
EA200301317A1 (ru) Производные аминохинолина и его применение в качестве лигандов аденозина a3
ATE182367T1 (de) Enzymatisches verfahren zur stereoselektiven herstellung einem enantiomer aus einem hetero bicyclischen alkohols
ATE446948T1 (de) Alpha-ketoamidderivativ, herstellungsverfahren und verwendung davon
DK248788D0 (da) Bicycliske sulfonamidderivater samt fremgangsmaade til fremstilling deraf
CO4940417A1 (es) DERIVADOS DE 2,3-DIHIDROFURO[3,2-b]PIRIDINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
AU4271389A (en) Phenylalkyl or phenylalkoxyethyl substituted piperazine derivatives

Legal Events

Date Code Title Description
FB Suspension of granting procedure